FORTEKOR PLUS 1.25 MG PIMOBENDAN/2.5 MG BENAZEPRIL HCL FOR DOGS

Land: Ástralía

Tungumál: enska

Heimild: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Virkt innihaldsefni:

BENAZEPRIL HYDROCHLORIDE; PIMOBENDAN

Fáanlegur frá:

ELANCO AUSTRALASIA PTY LTD

INN (Alþjóðlegt nafn):

pimobendan(1.25mg/Tb)+benazepril HCl(2.5mg/Tb)

Lyfjaform:

ORAL TABLET

Samsetning:

BENAZEPRIL HYDROCHLORIDE UNGROUPED Active 2.5 mg/Tb; PIMOBENDAN PYRIDAZINONE Active 1.25 mg/Tb

Einingar í pakka:

30 tablets; 60 tablets

Tegund:

VM - Veterinary Medicine

Framleitt af:

ELANCO AUSTRALASIA

Lækningarsvæði:

CARDIOVASCULAR SYSTEM

Vörulýsing:

Poison schedule: 4; Withholding period: WHP: N/A; Host/pest details: DOG: [CONGESTIVE HEART FAILURE]; For the treatment of congestive heart failure in dogs.See CONTRAINDICATIONS, PRECAUTIONS etc. on label.

Leyfisstaða:

Registered

Leyfisdagur:

2023-07-01

Upplýsingar fylgiseðill

:!
.~
AUSTRALIAN
GOVERNMENT
~
AUSTRALIAN PESTICIDES AND
VETERINARY MEDICINES AUTHORITY
APPENDIX 2
Ap~~!ed
TEMPLATE FOR RELEVANT LABEL PARTICULARS (RLPS)
(VETERINARY PRODUCTS)
Select appropriate:
1!1
New Product (include all applicable RLPs)
OR
D
Variation (highlight instructions that are being varied). Approval no.
of
label being varied:
Signal
heading:
Product
name:
Active
constituenUs:
Statement
of
CLAIMS:
Net
contents:
Action
Pharmacologic
al
Properties
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
FORTEKOR PLUS 1.25 mg PIMOBENDAN/2.5mg BENAZEPRIL
HCI
FOR DOGS
Each tablet contains:
1.25 mg Pimobendan
2.5
mg
Benazepril hydrochloride
FORTEKOR PLUS
is
indicated for the treatment
of
congestive heart failure
in
dogs.
30 TABLETS [60 TABLETS]
FORTEKOR PLUS
is
a combination
of
2 active substances: pimobendan and benazepril
hydrochloride.
Benazepril hydrochloride
is
an
inhibitor
of
angiotensin-converting enzyme (ACE), thus
reducing the blood pressure and volume load
on
the heart
in
dogs with congestive heart
failure. It has been shown that benazepril increased the time
to
worsening
of
heart failure,
and the time
to
death or withdrawal from the study, improved global clinical
condition,
reduced cough and improved exercise tolerance
in
dogs with symptomatic congestive heart
failure caused by valvular disease or dilated cardiomyopathy.
Benazepril hydrochloride
is
indicated for the treatment
of
left-sided heart failure
in
dogs,
most commonly resulting from Mitral Regurgitation (MR) (Endocardiosis)
and Dilated
Cardiomyopathy (DCM). Benazepril hydrochloride, by inhibiting the
renin angiotensin
aldosterone system (RAAS), minimises the undesirable effects
of
vasoconstriction and
sodium retention mediated by this system. The end result
is
an
improvement
in
the clinical
status
of
the dog. FORTEKOR leads
to
an
extension
of
the life span
of
dogs with heart
failure and also improves clinical signs, notably a reduction
in
coughing, and improvement
to
the quality
of
life.
Pimobendan
is
a non-sympa